{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.27","upperLimit":"0.58","value":"0.424"},{"groupId":"OG001","lowerLimit":"0.05","upperLimit":"0.54","value":"0.298"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who had sub-total resection initially. The event-free survival (EFS) defined as the date of disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start date of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.","dispersionType":"95% Confidence Interval","groups":[{"description":"Differentiated ependymoma:tumor pathology by central review.","id":"OG000","title":"Differentiated Ependymoma"},{"description":"Anaplastic ependymoma:tumor pathology by central review.","id":"OG001","title":"Anaplastic Ependymoma"}],"paramType":"NUMBER","populationDescription":"Of 64 eligible patients who had initial subtotal resection, 5 patients were off-therapy prior to radiation therapy, and 4 patients had a disease progression prior to radiation therapy. There were 55 eligible patients included in the analysis. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability.","reportingStatus":"POSTED","timeFrame":"At 5 years since the time of radiation therapy.","title":"Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Probability of EFS at 5 years"}